{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:44:16Z","timestamp":1780569856719,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WS726958"],"award-info":[{"award-number":["WS726958"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.schres.2017.09.014","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T19:03:02Z","timestamp":1505502182000},"page":"260-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pregabalin for anxiety in patients with schizophrenia \u2014 A randomized, double-blind placebo-controlled study"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-0912","authenticated-orcid":false,"given":"Ole","family":"Schjerning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Damkier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Engelhardt","family":"Lykkegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus Damgaard","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr. Serv."},{"issue":"9","key":"10.1016\/j.schres.2017.09.014_bb0015","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J. Pain"},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale\u2014revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2007-984400","article-title":"Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials","volume":"40","author":"Bech","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1039856215588207","article-title":"How should we manage anxiety in patients with schizophrenia?","volume":"23","author":"Bosanac","year":"2015","journal-title":"Australas. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.09.014_bb0035","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.comppsych.2004.07.009","article-title":"Anxiety disorders in schizophrenia","volume":"45","author":"Braga","year":"2004","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.09.014_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2013.07.030","article-title":"Anxiety comorbidity in schizophrenia","volume":"210","author":"Braga","year":"2013","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.schres.2017.09.014_bb0045","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"6","key":"10.1016\/j.schres.2017.09.014_bb0050","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1185\/03007995.2012.684044","article-title":"Characterizing and understanding body weight patterns in patients treated with pregabalin","volume":"28","author":"Cabrera","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0055","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/JCP.0b013e3181e5c095","article-title":"Augmentation with pregabalin in schizophrenia","volume":"30","author":"Englisch","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.09.014_bb0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.09.014_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","article-title":"Long-term efficacy of pregabalin in generalized anxiety disorder","volume":"23","author":"Feltner","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.09.014_bb0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"issue":"special issue","key":"10.1016\/j.schres.2017.09.014_bb0080","first-page":"76","article-title":"Diagnosis and rating of anxiety","volume":"3","author":"Hamilton","year":"1969","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.09.014_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00213-005-0172-7","article-title":"A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers","volume":"183","author":"Hindmarch","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2-3","key":"10.1016\/j.schres.2017.09.014_bb0090","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0920-9964(99)00151-6","article-title":"Quality of life in schizophrenia: contributions of anxiety and depression","volume":"51","author":"Huppert","year":"2001","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.09.014_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2-3","key":"10.1016\/j.schres.2017.09.014_bb0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.09.014_bb0105","series-title":"Dementia Praecox and Paraphrenia","author":"Kraepelin","year":"1919"},{"key":"10.1016\/j.schres.2017.09.014_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"12","key":"10.1016\/j.schres.2017.09.014_bb0115","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2017.09.014_bb0120","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4088\/JCP.v62n1109","article-title":"Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder","volume":"62","author":"Meoni","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.09.014_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2017.09.014_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/08039480500504966","article-title":"Quality of life in schizophrenic patients: association with depressive symptoms","volume":"60","author":"Norholm","year":"2006","journal-title":"Nord. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.09.014_bb0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.seizure.2006.02.004","article-title":"Pregabalin-associated acute psychosis and epileptiform EEG-changes","volume":"15","author":"Olaizola","year":"2006","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.schres.2017.09.014_bb0140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.09.014_bb0145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.jcp.0000117423.05703.e7","article-title":"Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study","volume":"24","author":"Pande","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.09.014_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.schres.2017.09.014_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing","volume":"25","author":"Pohl","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2017.09.014_bb0160","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.09.014_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: a systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2017.09.014_bb0170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0028-1112128","article-title":"Pregabalin in the treatment of schizophrenic anxiety","volume":"42","author":"Schonfeldt-Lecuona","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.09.014_bb0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0b013e3181ccc6ef","article-title":"Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial","volume":"74","author":"Simpson","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.schres.2017.09.014_bb0180","first-page":"1","article-title":"Possible error in the Danish version of the WHO Quality of Life (WHOQOL-BREF) Questionnaire","author":"Thomsen","year":"2017","journal-title":"Nord. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.09.014_bb0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1-3","key":"10.1016\/j.schres.2017.09.014_bb0190","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.schres.2011.03.001","article-title":"Characteristics and predictors of long-term institutionalization in patients with schizophrenia","volume":"131","author":"Uggerby","year":"2011","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.09.014_bb0195","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group","volume":"28","author":"WHOQOL-Group","year":"1998","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2017.09.014_bb0200","series-title":"WHOQOL User Manual","author":"World Health Organization","year":"1998"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417305753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417305753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T19:26:09Z","timestamp":1602962769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417305753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"alternative-id":["S0920996417305753"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.09.014","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregabalin for anxiety in patients with schizophrenia \u2014 A randomized, double-blind placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}